The Biopharmaceutical Industry Provides 75% Of The FDA's Drug Review Budget. Is This A Problem?

URL

https://www.forbes.com/sites/johnlamattina/2018/06/28/the-biopharmaceutical-industry-provides-75-of-the-fdas-drug-review-budget-is-this-a-problem/

Authors

John LaMattina

Published Date

June 28, 2018

Publication

Forbes

FORBES® Terms of Service
https://www.forbes.com/terms-and-conditions/#23ab45fa193f

You may use the Website, Forbes Channels, and Content online and solely for personal, non-commercial, and informational/entertainment use, and you may download or print a single copy of any downloadable portion of the Content, where permitted, for your personal, non-commercial, and informational use, provided you do not remove any trademark, copyright or other notice contained in such Content. No other use is permitted without securing the prior written consent of Forbes.

Medium

document

Topics

bioethics,COVID-19,financial incentives influence,manufacturers,manufacturers US government contracts